SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Secret_Agent_Man who started this subject8/28/2002 2:35:48 PM
From: tuck   of 508
 
FWIW, from Briefing.com,

>>11:06AM InterMune estimates cut by Lehman (ITMN) 21.03 +3.03: -- Update -- Lehman says that ITMN's mixed Phase III results for Actimmune in idiopathic pulmonary fibrosis (IPF) will make FDA approval very difficult for that indication, though perhaps not impossible; however, drug should still see growing sales as it is already on the mkt and may still be prescribed; new sales ests for IPF are $164.7 mln in 2003 and $224.1 mil in 2004, down from prior ests of $215.6 mln and $305.8 mln, respectively; new ests assume no FDA approval of an sBLA and a challenging reimbursement environment. Cuts 2003 est to ($2.74) from ($1.73). Price target is $34.<<

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News